Dianabol

Dianabol profile

Metandienone, also known as methandienone or methandrostenolone, is sold under the brand name Dianabol (D-Bol) among others. It is an androgen and anabolic steroid (AAS) medication. It is still quite often used because of its affordability. It is also effective for bulking cycles.  It is also used non-medically for physique- and performance-enhancing purposes.  It is often taken by mouth.

Side effects of metandienone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. The drug causes estrogenic effects like fluid retention and breast enlargement. It can also lead to liver damage. The drug is an agonist of the androgen receptor (AR). It is the biological target of androgens like testosterone and dihydrotestosterone (DHT). The drug has strong anabolic effects and moderate androgenic effects.^[1] It also has moderate estrogenic effects.

Metandienone was originally developed in 1955 by CIBA and marketed in Germany and the United States. As the CIBA product Dianabol, metandienone quickly became the first widely used AAS among professional and amateur athletes. It remains the most common orally active AAS for non-medical use. It is currently a controlled substance in the United States and United Kingdom and remains popular among bodybuilders. Metandienone is readily available without a prescription in certain countries such as Mexico. It is also manufactured in some Asian countries.

Medical uses of Dianabol

Metandienone was formerly approved and marketed as a form of androgen replacement therapy for the treatment of hypogonadism in men. It has since been discontinued and withdrawn in most countries, including in the United States.

It was given at a dosage of 5 to 10 mg/day in men and 2.5 mg/day in women.

Available forms of Dianabol

Metandienone was provided in the form of 2.5, 5 mg and 10mg oral tablets.

Non-medical uses

Metandienone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. It is said to be the most widely used AAS for such purposes both today and historically.

Side effects

Androgenic side effects such as oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and virilization may occur.^[1] Estrogenic side effects such as gynecomastia and fluid retention can also occur.^[1] Case reports of gynecomastia exist.^[21][22] As with other 17α-alkylated steroids, methandienone poses a risk of hepatotoxicity. Use over extended periods of time can result in liver damage without appropriate precautions.^[1]

Pharmacology

Pharmacodynamics

Methandienone binds to and activates the androgen receptor (AR) in order to exert its effects. These include dramatic increases in protein synthesis, glycogenolysis, and muscle strength over a short space of time. While the drug can be metabolized by 5α-reductase into methyl-1-testosterone (17α-methyl-δ¹-DHT), it has extremely low affinity for this enzyme. Methyl-1-testosterone is thus produced in only trace amounts. As such,  5α-reductase inhibitors like finasteride and dutasteride do not reduce the androgenic effects of metandienone. The ratio of anabolic to androgenic activity of metandienone is improved relative to that of testosterone. However, the drug does still possess moderate androgenic activity. The ratio of anabolic to androgenic activity of metandienone is improved relative to that of testosterone. However, the drug does still possess moderate androgenic activity. It is capable of producing severe virilization in women and children. As such, it is only really commonly used in men.

Metandienone is a substrate for aromatase and can be metabolized into the estrogen methylestradiol (17α-methylestradiol). The rate of aromatization is reduced relative to that for testosterone or methyltestosterone. However, the estrogen produced is metabolism-resistant. Hence, metandienone retains moderate estrogenic activity.As such, it can cause side effects such as gynecomastia and fluid retention. Antiestrogens are co-administered to reduce estrogenic side effects. These include aromatase inhibitors such as anastrozole or selective estrogen receptor modulators such as tamoxifen. Metandienone has no progestogenic activity.

As with other 17α-alkylated AAS, metandienone may be hepatotoxic, especially with prolonged use of high doses.

Pharmacokinetics

Metandienone has high oral bioavailability. It has very low affinity for human serum sex hormone-binding globulin (SHBG). About 10% of that of testosterone. Only 2% of that of DHT. The drug is metabolized in the liver by 6β-hydroxylation, 3α- and 3β-oxidation, 5β-reduction, 17-epimerization, and conjugation among other reactions. Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. The elimination half-life of metandienone is about 3 to 6 hours. It is eliminated in the urine.

Chemistry

See also: List of androgens/anabolic steroids

Metandienone, also known as 17α-methyl-δ¹-testosterone or as 17α-methylandrost-1,4-dien-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone. It is a modification of testosterone with a methyl group at the C17α position. It also has an additional double bond between the C1 and C2 positions. The drug is also the 17α-methylated derivative of boldenone (δ¹-testosterone) and the δ¹ analogue of methyltestosterone (17α-methyltestosterone).

Detection in body fluids

Metandienone is subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary urinary metabolites are detectable for up to 3 days. A recently discovered hydroxymethyl metabolite is found in urine for up to 19 days. This occurs after a single 5 mg oral dose. Several of the metabolites are unique to metandienone. Methods for detection in urine specimens usually involve gas chromatography-mass spectrometry.

History

Metandienone was first described in 1955. It was synthesized by researchers at the CIBA laboratories in Basel, Switzerland. CIBA filed for a U.S. patent in 1957, and began marketing the drug as Dianabol in 1958 in the U.S. It was initially prescribed to burn victims and the elderly. It was also prescribed off-label as a pharmaceutical performance enhancement to weight lifters and other athletes. Early adopters included players for Oklahoma University. Head coach of San Diego Chargers, Sid Gillman administered Dianabol to his team starting in 1963.

After the Kefauver Harris Amendment was passed in 1962, the U.S. FDA began the DESI review process. This was to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards. These drugs included Dianabol. In 1965, the FDA pressured CIBA to further document its legitimate medical uses. The FDA then re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism. After CIBA’s patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the U.S.

Following further FDA pressure, CIBA withdrew Dianabol from the U.S. market in 1983. Generic production shut down two years later, when the FDA revoked metandienone’s approval entirely in 1985. Non-medical use was outlawed in the U.S. under the Anabolic Steroids Control Act of 1990. While metandienone is controlled and no longer medically available in the U.S., it continues to be produced and used medically in some other countries.

Society and culture

Generic names

Metandienone is the generic name of the drug. It is its INN Tooltip International Nonproprietary Name. Methandienone is its BAN Tooltip British Approved Name. Métandiénone is its DCF Tooltip Dénomination Commune Française. It is also referred to as methandrostenolone and as dehydromethyltestosterone. The former synonym should not be confused with methylandrostenolone. It is another name for a different AAS known as metenolone.

Brand names

Metandienone was introduced and formerly sold primarily under the brand name Dianabol. It has been marketed under a variety of other brand names. These include Anabol, Averbol, Chinlipan, Danabol, Dronabol, Metanabol, Methandon, Naposim, Reforvit-B, and Vetanabol among others.

Legal status

Metandienone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act.